Ocular Therapeutix share: Surprising success on the market!

Executives sell shares to cover taxes, while positive analyst estimates and progress in AMD therapy Axpaxli strengthen the company's profile.

Biotechnology company Ocular Therapeutix, Inc. (NASDAQ: OCUL), with a market capitalization of $1.06 billion, recently saw several stock sales by its leadership team. Executive Chairman, President and CEO Pravin Dugel sold 21,475 shares at an average price of $6.87, for a total value of approximately $147,533. This transaction was made as part of a pre-determined trading plan established on February 21, 2024. Following this sale, Dugel will continue to directly hold 3,520,318 shares of the company. Similar sales were also made by Chief Scientific Officer Jeffrey S. Heier, who sold 3,061 shares for a total of $21,029, and Chief Strategy Officer Sanjay Nayak, who sold 1,895 shares valued at approximately $12,961. All three transactions served to cover tax obligations related to the transfer of restricted stock units and were not discretionary trading transactions.

Clinical advances influence analyst estimates

Ocular Therapeutix stock is currently the focus of investor interest, particularly due to progress in clinical trials for Axpaxli, a drug to treat wet age-related macular degeneration (AMD). The Phase 3 SOL-1 trial has successfully randomized over 300 patients, with initial results expected in the fourth quarter of 2025. This rapid patient enrollment indicates strong interest in the potential therapy. Several analysts are positive on the stock: Raymond James reiterated a "Strong Buy" rating with a price target of $19.00, HC Wainwright reiterated a "Buy" rating with a price target of $15.00, and Baird maintained its "Outperform" rating with a price target of $17.00. Technical indicators suggest the stock may currently be oversold, providing potential buying opportunities. The company's quarterly results are expected on March 6, 2025.

Advertisement

Ocular Therapeutix share: Buy or sell?! New Ocular Therapeutix analysis from February 27 provides the answer:

The latest Ocular Therapeutix figures speak a clear language: urgent need for action for Ocular Therapeutix shareholders. Is it worth getting in or should you sell? Find out what to do now in the current free analysis from February 27th.

Ocular Therapeutix: Buy or sell? Read more here...